iuvando Health and Immatics collaborate to improve access to clinical trials for patients with metastatic melanoma
Mannheim (ots)
iuvando Health, a leading health tech company specializing in clinical trials matching and physician-led patient navigation support, today announced its collaboration with Immatics, the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, to improve access to clinical trials for patients with metastatic melanoma in Germany.
Despite significant advances in the treatment of metastatic melanoma, many patients still face considerable challenges in identifying and accessing appropriate clinical trials. Limited awareness of available studies, complex eligibility criteria, geographical barriers, and the need for timely referral often prevent patients from participating in potentially promising clinical research. Together, Immatics and iuvando Health aim to address these barriers by combining Immatics' commitment to advancing innovative therapies with iuvando Health's personalized clinical trial matching and physician-led patient navigation support.
"Clinical trials play a critical role in advancing new treatment options for patients with metastatic melanoma, yet far too many patients are unable to access studies that may be appropriate for them," said Cedrik Britten, M.D., Chief Medical Officer at Immatics. "At Immatics, we are committed to making a meaningful impact on the lives of patients with cancer and, by working with iuvando Health, our goal is to help patients and their physicians in navigating and accessing clinical trials in Germany."
"Every patient deserves the opportunity to understand their full range of treatment options including clinical trials," said Mridul Agrawal, M.D., CEO & Co-Founder at iuvando Health. "For many patients with metastatic melanoma, finding a suitable clinical trial remains unnecessarily difficult despite the availability of promising research. By combining Immatics' scientific innovation with iuvando Health's physician-led patient navigation, we aim to help bridge this gap. Our shared goal is to empower patients with personalized support and connect them with potentially life-saving treatment options that may otherwise remain out of reach."
The collaboration reflects a shared commitment to placing patients at the center of clinical research. By increasing awareness of clinical trial opportunities and simplifying access through personalized navigation, Immatics and iuvando Health aim to improve the overall patient experience, thereby supporting the development of future treatments for metastatic melanoma.
About iuvando Health
iuvando Health is a leading European oncology healthtech company with the mission of improving access to the most advanced cancer treatments available through clinical trials. By combining data-driven, personalized clinical trial matching with physician-led patient navigation, iuvando helps cancer patients to find and access clinical studies that may be relevant to their individual diagnosis and treatment history.
iuvando is an official supporter of Germany's National "Against Cancer" (Nationale Dekade gegen Krebs) initiative of the Federal Ministry of Research, Technology and Space (BMFTR). The company's innovative and patient-centered approach has been recognized with numerous national and international awards.
Further information: iuvando.de
Pressekontakt:
Dr. Mridul Agrawal
+49 621 6374 5504
info@iuvando.de
Original content of: iuvando Health GmbH, transmitted by news aktuell